Pharming Group N.V.

NASDAQ:PHAR

Biotechnology

Healthcare
$12.48 +2.19%

+$0.28 today

Market cap
$882.43M
Beta
0.10
P/E (TTM)
77.0
EPS (TTM)
$0.02
52W Low $9.54High $21.34

Volume 0.01M

Average 0.01M

Fair Value & DCF

Compare our fair value with your own assumptions

Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.

Pharming Group N.V.

NASDAQ:PHAR

Intrinsic Alpha fair value

Locked

Current Price

$12.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Build your own valuation

Test an independent scenario and compare it with Intrinsic Alpha's estimate.

Sign in to use the DCF calculator

Free accounts get 5 valuations per week. Upgrade for more.

Sign in / Sign up

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/A-37.0%
+69.5% (5yr)1 analysts
RevenueN/AN/A+22.4%
+11.2% (5yr)2 analysts
Net IncomeN/AN/A-40.6%
+69.4% (5yr)2 analysts
EBITN/AN/A+4.6%
+24.5% (5yr)2 analysts

Analysis

Recent growth has been strongest in Revenue at +22.4% over three years. Forward estimates point to EPS at +69.5% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Estimates & History

Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.

Further estimates hidden. Sign in to unlock

Competitor Valuations

Peer stocks ranked by intrinsic value status

CompanyMarket CapPriceValuationP/E1Y Return

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

$11.09B$57.23Undervalued39.4+13.42%

Ionis Pharmaceuticals, Inc.

NASDAQ:IONS

$4.84B$29.06Not rated-37.5-63.23%

Pharvaris N.V.

NASDAQ:PHVS

$2.34B$33.36Not rated-11.0+31.62%

BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

$1.96B$7.61Undervalued-4.8+4.29%

Stoke Therapeutics, Inc.

NASDAQ:STOK

$1.75B$26.68Undervalued-11.1-7.71%

Intellia Therapeutics, Inc.

NASDAQ:NTLA

$1.36B$9.70Not rated-4.6+15.35%

Silence Therapeutics plc

NASDAQ:SLN

$936.65M$19.83Not rated-3.9+193.63%

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

$252.48M$2.30Not rated-1.7-28.23%

ProQR Therapeutics N.V.

NASDAQ:PRQR

$198.98M$1.41Not rated-3.8-47.12%